MORDOR II: Persistence of Benefit of Azithromycin for Childhood Mortality

Background. MORDOR I found that 2 years of biannual mass azithromycin administration reduced post-neonatal childhood mortality by 18% in Niger. Over time, this benefit could increase with each distribution or wane due to antibiotic resistance. Here in MORDOR II, we treated communities in both arms f...

Descripción completa

Detalles Bibliográficos
Autores principales: Keenan, Jeremy D., Arzika, Ahmed M., Maliki, Ramatou, Boubacar, Nameywa, Elh Adamou, Sanoussi, Moussa Ali, Maria, Cook, Catherine, Lebas, Elodie, Lin, Ying, Ray, Kathryn J., O’Brien, Kieran S., Doan, Thuy, Oldenburg, Catherine E., Callahan, E. Kelly, Emerson, Paul M., Porco, Travis C., Lietman, Thomas M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512890/
https://www.ncbi.nlm.nih.gov/pubmed/31167050
http://dx.doi.org/10.1056/NEJMoa1817213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512890/
https://www.ncbi.nlm.nih.gov/pubmed/31167050
http://dx.doi.org/10.1056/NEJMoa1817213

Ejemplares similares